deucravacitinib deucravacitinib deucravacitinib, sold under the brand name sotyktu, is medication used for the treatment of moderate-to-severe plaque psoriasis. it is a tyrosine kinase 2 (tyk2) inhibitor and it is taken by mouth. it was developed by bristol myers squibb. deucravacitinibclinical datapronunciation/duːˌkrævəˈsɪtɪnɪb/doo-kra-və-si-ti-nib trade namessotyktuother namesbms-986165ahfs/drugs.commonographlicense data us dailymed: deucravacitinib pregnancycategory au: b1 routes ofadministrationby mouthatc codel04aa56 (who) legal statuslegal status au: s4 (prescription only) ca: ℞-only us: ℞-only eu: rx-only pharmacokinetic databioavailability99%protein binding82–90%metabolismliver (primarily cyp1a2)metabolitesbmt-153261 (active)elimination half-life10 hoursexcretionfeces, urineidentifiers iupac name 6-(cyclopropanecarbonylamido)-4--n- (trideuteriomethyl)pyridazine-3-carboxamide cas number1609392-27-9pubchem cid134821691drugbankdb16650chemspider72380005uniin0a21n6raukeggd11817chemblchembl435170echa infocard100.329.069 chemical and physical dataformulac20h19d3n8o3molar mass425.466 g·mol−13d model (jsmol)interactive image smiles c()()nc(=o)c1=nn=c(c=c1nc2=cc=cc(=c2oc)c3=nn(c=n3)c)nc(=o)c4cc4 inchi inchi=1s/c20h22n8o3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11h,7-8h2,1-3h3,(h,21,30)(h2,23,24,25,29)/i1d3key:bzzkepgenylqsc-fibgupnxsa-n deucravacitinib was approved for medical use in the united states in september 2022, and in australia in december 2022. the us food and drug administration (fda) considers it to be a first-in-class medication. medical uses deucravacitinib is mechanism of action it acts as a highly selective allosteric inhibitor of non-receptor tyrosine-protein kinase 2 (tyk2). molecule design the chemical structure of deucravacitinib contains a methyl amide in which all three hydrogen atoms are replaced by deuterium. society and culture legal status on 26 january 2023, the committee for medicinal products for human use (chmp) of the european medicines agency (ema) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product sotyktu, intended for the treatment of moderate to severe psoriasis. the applicant for this medicinal product is bristol-myers squibb pharma eeig. deucravacitinib was approved for medical use in the european union in march 2023.